CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

PR Newswire Pharma
Original article

Ivonescimab Versus Pembrolizumab in First-Line PD-L1-Positive NSCLC: Positive Overall Survival Results from HARMONi-2 Presented at WCLC 2026

Phase 3IvonescimabPembrolizumab
Related Companies

Read the original article

Published by PR Newswire Pharma on September 13, 2026 6:59 AM

Read Original